The early identification of disease progression in patients with suspected infection presenting to the emergency department: a multi-centre derivation and validation study
Open Access
- 8 February 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Critical Care
- Vol. 23 (1), 1-15
- https://doi.org/10.1186/s13054-019-2329-5
Abstract
There is a lack of validated tools to assess potential disease progression and hospitalisation decisions in patients presenting to the emergency department (ED) with a suspected infection. This study aimed to identify suitable blood biomarkers (MR-proADM, PCT, lactate and CRP) or clinical scores (SIRS, SOFA, qSOFA, NEWS and CRB-65) to fulfil this unmet clinical need. An observational derivation patient cohort validated by an independent secondary analysis across nine EDs. Logistic and Cox regression, area under the receiver operating characteristic (AUROC) and Kaplan-Meier curves were used to assess performance. Disease progression was identified using a composite endpoint of 28-day mortality, ICU admission and hospitalisation > 10 days. One thousand one hundred seventy-five derivation and 896 validation patients were analysed with respective 28-day mortality rates of 7.1% and 5.0%, and hospitalisation rates of 77.9% and 76.2%. MR-proADM showed greatest accuracy in predicting 28-day mortality and hospitalisation requirement across both cohorts. Patient subgroups with high MR-proADM concentrations (≥ 1.54 nmol/L) and low biomarker (PCT < 0.25 ng/mL, lactate < 2.0 mmol/L or CRP < 67 mg/L) or clinical score (SOFA < 2 points, qSOFA < 2 points, NEWS < 4 points or CRB-65 < 2 points) values were characterised by a significantly longer length of hospitalisation (p < 0.001), rate of ICU admission (p < 0.001), elevated mortality risk (e.g. SOFA, qSOFA and NEWS HR [95%CI], 45.5 [10.0–207.6], 23.4 [11.1–49.3] and 32.6 [9.4–113.6], respectively) and a greater number of disease progression events (p < 0.001), compared to similar subgroups with low MR-proADM concentrations (< 1.54 nmol/L). Increased out-patient treatment across both cohorts could be facilitated using a derivation-derived MR-proADM cut-off of < 0.87 nmol/L (15.0% and 16.6%), with decreased readmission rates and no mortalities. In patients presenting to the ED with a suspected infection, the blood biomarker MR-proADM could most accurately identify the likelihood of further disease progression. Incorporation into an early sepsis management protocol may therefore aid rapid decision-making in order to either initiate, escalate or intensify early treatment strategies, or identify patients suitable for safe out-patient treatment.Funding Information
- Thermo Fisher (N/A)
This publication has 47 references indexed in Scilit:
- Biomarker-enhanced triage in respiratory infections: a proof-of-concept feasibility trialEuropean Respiratory Journal, 2013
- Proadrenomedullin Improves Risk of Early Admission to ICU Score for Predicting Early Severe Community-Acquired PneumoniaSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Utility of Procalcitonin (PCT) and Mid regional pro-Adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in Emergency Department (ED). A comparison with APACHE II scoreBMC Infectious Diseases, 2012
- Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: Derivation of a clinical algorithmBMC Infectious Diseases, 2011
- Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised QstatisticsBMC Medical Research Methodology, 2011
- Midregional Proadrenomedullin as a Prognostic Tool in Community-Acquired PneumoniaSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2009
- The influence of corticosteroids on the release of novel biomarkers in human endotoxemiaIntensive Care Medicine, 2007
- Adrenomedullin and endothelial barrier functionThrombosis and Haemostasis, 2007
- Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock*Critical Care Medicine, 2006
- C-reactive protein as an indicator of resolution of sepsis in the intensive care unitIntensive Care Medicine, 1995